Latest Breaking News On - லூக் பெர்த்தியாம் - Page 1 : comparemela.com

New drug target valid for breast cancer as well as lymphoma One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research. The results provide more justification and rationale for starting the clinical trial in May. It s another exciting stepping stone to finding out if this is going to be a new cancer treatment. John Mackey, First Author, Professor and Director of Oncology Clinical Trials, Faculty of Medicine & Dentistry, University of Alberta The drug PCLX-001 is designed to selectively kill cancer cells by targeting enzymes involved in myristoylation, a process key to the cell signaling system that is often defective in cancer cells. The molecule was originally developed by the University of Dundee as a treatment for African sleeping sickness. U of A cell biologist Luc Berthiaume was the first to realize it could work aga

John mackeyLuc berthiaumeEmily hendersonCross cancer institute in edmontonUniversity of albertaAlberta cancer foundationCure cancer foundationUniversity of dundeePacylex pharmaceuticalsCross cancer instituteCure cancerCancer treatmentBreast cancerClinical trialஜான் மேக்கிலூக் பெர்த்தியாம்